One68 Global Capital’s TherapeuticsMD TXMD Stock Holding History

One68 Global Capital’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-622	Closed	-$75K	–	51
2019 Q4	$75K	Buy	+622	New	+$89.4K	0.16%	77

Other funds holding TXMD

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

One68 Global Capital's TXMD Position: Q1 2020 in Review

One68 Global Capital sold out of TherapeuticsMD (TXMD) in Q1 2020, closing a stake of 622 shares — an estimated $75K sold.

One68 Global Capital first reported a position in TXMD in Q4 2019 and held it in 1 quarter. The position peaked at $75K in Q4 2019. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2020.

One68 Global Capital reported no remaining TherapeuticsMD position as of Q1 2020 after selling out during the quarter.
One68 Global Capital sold 622 TherapeuticsMD shares in Q1 2020, an estimated $75K.
One68 Global Capital first reported a position in TherapeuticsMD in Q4 2019 and held it in 1 quarter.
One68 Global Capital's TherapeuticsMD position peaked at $75K in Q4 2019.
143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2020.

Based on One68 Global Capital's 13F filing for Q1 2020, filed 15 May 2020.